Unusual, Uncommon, Intriguing, and Significant Causes of Kounis Syndrome: Important Medications and Chemicals Used to Treat Kounis Syndrome and Myocardial Infarction Can Cause Kounis Syndrome
Kounis NG, de Gregorio C, Hung MY, Giamouzis G, Michalaki MA, Özkan U, Ceasovschih A, Mplani V, Dousdampanis P, Kouni SN, Stefanidis A, Nastouli KM, Bozika M, Patsouras N, Koniari I (2025) · Journal of Cardiovascular Development and Disease · n=0
Study Profile
- Design
- narrative review of mast-cell-mediated Kounis (allergic) coronary syndrome with explicit discussion of hirudotherapy as a recognized trigger of mast cell degranulation and acute coronary ischemia (multicenter international authorship: Greece, Italy, Taiwan, Turkey, Romania, UK)
- Sample size (n)
- —
- Intervention
- Narrative synthesis of case literature implicating hirudotherapy (whole-leech application) and several anti-thrombotic / anti-ischemic medications (heparin, protamine, adrenaline, aspirin, clopidogrel, corticosteroids) as Kounis syndrome triggers
- Comparator
- Not applicable — narrative review without quantitative comparator
- Primary endpoint
- Identification and tabulation of unusual triggers of Kounis syndrome, including hirudotherapy
- Primary result
- Authors include hirudotherapy among recognized triggers of Type I/II Kounis syndrome; pathway is mast-cell degranulation with histamine, tryptase, arachidonic acid derivatives, and chymase release driving coronary spasm and platelet activation; clinicians who use leech therapy should be aware of this rare but life-threatening allergic-cardiovascular intersection
- Follow-up duration
- Not applicable — review
- PMID
- 41295349
Key Findings
- Hirudotherapy explicitly identified as a recognized trigger of Type I (allergic vasospasm) and Type II (allergic plaque rupture) Kounis syndrome
- Mast-cell mediators (histamine, tryptase, chymase, arachidonic acid derivatives) drive the cascade — consistent with biology of leech-bite hypersensitivity
- Clinical conundrum noted: multiple drugs used to TREAT Kounis (epinephrine, heparin, aspirin, corticosteroids) can also trigger it — relevant when managing leech-bite reactions
- Authors recommend physician awareness when patients with allergic history receive hirudotherapy
- Adds to the growing safety-context literature alongside Tas 2025 (leech-bite Kounis case) and Wanandy 2024 (Tasmania anaphylaxis)
Limitations
- Narrative review — does not provide incidence estimates for hirudotherapy-related Kounis syndrome
- Case literature on leech-bite Kounis remains small (single-digit case reports)
- Mechanistic discussion based on extrapolation from other mast-cell-mediated triggers
- No prospective screening data for at-risk leech-therapy patients
- Review covers a heterogeneous mix of triggers — leech therapy is one of many
Clinical Implications
Kounis 2025 adds an important cardiology-allergy safety signal to ASH's leech-therapy literature. For US clinicians administering hirudotherapy under the K040187 device indication, the review reinforces that patients with known mast-cell disorders, hymenoptera allergy, or prior leech hypersensitivity should be screened pre-procedure and treated only in monitored settings with rapid access to epinephrine. The review complements existing case-report literature (Tas 2025, Wanandy 2024) and supports current ASH practice of informed-consent disclosure of rare anaphylactic risk.
Related Trials
Leech Me Alone! Atraumatic Hemarthrosis after Hirudotherapy
Curcio J, Lloyd CM (2020)
Leech-bite induced anaphylaxis with or without Hymenoptera venom sensitization
Wanandy T, Bradley I, Tovar Lopez CD, Cotton BTB, Handley SA, Mulcahy EM, Adriana Le TT, Lau WY (2024)
Time to Reconsidering the Potential Role of Leech Salivary Proteins in Medicine: Type-II Kounis Syndrome Triggered by Leech Bite
Tas S, Yildiz BS, Ersin A, Tas U (2025)
Non-Occlusive Mesenteric Ischemia Due to Hirudotherapy: A Case Report
Akalın Ç, Ekmen N (2020)